Targeting the MLL complex in castration resistant prostate cancer

Resistance to androgen deprivation therapies and increased androgen receptor (AR) activity are major drivers of castration resistant prostate cancer (CRPC). Although prior work focused on targeting AR directly, co-activators of AR signaling—which may represent new therapeutic targets—are relatively...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Nat Med
Autors principals: Malik, Rohit, Khan, Amjad P., Asangani, Irfan A., Cieślik, Marcin, Prensner, John R., Wang, Xiaoju, Iyer, Matthew K., Jiang, Xia, Borkin, Dmitry, Escara-Wilke, June, Stender, Rachell, Wu, Yi-Mi, Niknafs, Yashar S., Jing, Xiaojun, Qiao, Yuanyuan, Palanisamy, Nallasivam, Kunju, Lakshmi P., Krishnamurthy, Pranathi M., Yocum, Anastasia K., Mellacheruvu, Dattatreya, Nesvizhskii, Alexey I., Cao, Xuhong, Dhanasekaran, Saravana M., Feng, Felix Y., Grembecka, Jolanta, Cierpicki, Tomasz, Chinnaiyan, Arul M.
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4390530/
https://ncbi.nlm.nih.gov/pubmed/25822367
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nm.3830
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars